APG350
/ Apogenix, AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 22, 2018
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
(PubMed, Cell Death Dis)
- "In conclusion, APG350 represents a promising next-generation TRA for the treatment of PDAC. Moreover, our results suggest that combining APG350 with Navitoclax might be a succesfull strategy for cancers harboring mitochondrial apoptosis resistance."
Journal
1 to 1
Of
1
Go to page
1